From: Angiogenesis in Interstitial Lung Diseases: a pathogenetic hallmark or a bystander?
Investigator (year) | Tissue samples Sample size | Studied Parameters | Summary | Limitations |
---|---|---|---|---|
Agostini et al. 69 (1998) | Lung specimens/BALF samples/24 patients/6 controls | CXCL10 | Increased expression of CXCL10 in sarcoid tissues / Positive relation of elevated CXCL10 BALF levels with T cell alveolitis | Lack of knowledge regarding regulators of CXCL10 expression / Incomplete analysis of the Th1 response / Small sample size |
Miotto et al. 70 (2001) | Lung specimens/BALF/ 39 patients/10 controls | CXCL10, MCPs, eotaxin | Increased expression of CXCL10 levels in sarcoidosis patients | Expression of CXCL10 not selective for Th1 mediated response / Lack of association with parameters of disease severity |
Sekiya et al. 72 (2003) | Serum samples/33 patients | VEGF | VEGF as a prognosticator of disease activity and extent | Retrospective analysis No serial measurement / No relation with serological parameters of disease severity / Limited number of patients |
Katoh et al. 71 (2005) | BALF and serum samples | CXCL9, 10 | Increased BALF concentrations in sarcoidosis patients | Discrepancies between BALF and serum levels / No relation with clinical parameters of disease severity |